Invitation to Saniona Q2 investor call on 27 August 2026

2026-08-20 08:00:00

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, will host a Q2 investor call on 27 August 2026, at 11.00 CEST.

At the call Management will be presenting results and a company update. At the end of the presentation there will be a Q&A session, where participants can ask online questions.

Access to the event can be obtained through the following link:

Live Q: Saniona - Redeye

REPLAY access
Webcast replay will be available at www.saniona.com and at www.redeye.se

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for pediatric epilepsy syndromes, SAN2219 for epilepsy, and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico and Argentina. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, Cephagenix, and AstronauTx, which holds worldwide rights to ATX0926. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode